KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Tax Provisions (2021 - 2026)

Pacific Biosciences Of California has reported Tax Provisions over the past 4 years, most recently at $202000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 36.08% year-over-year to $202000.0; the TTM value through Dec 2025 reached $318000.0, up 0.63%, while the annual FY2025 figure was $318000.0, 0.63% up from the prior year.
  • Tax Provisions for Q4 2025 was $202000.0 at Pacific Biosciences Of California, down from $383000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $1.2 million in Q4 2021 and troughed at -$10.7 million in Q3 2023.
  • A 4-year average of -$1.2 million and a median of $118500.0 in 2025 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: soared 144.01% in 2024 and later crashed 36.08% in 2025.
  • Year by year, Tax Provisions stood at $1.2 million in 2021, then crashed by 161.11% to -$718000.0 in 2023, then soared by 144.01% to $316000.0 in 2024, then tumbled by 36.08% to $202000.0 in 2025.
  • Business Quant data shows Tax Provisions for PACB at $202000.0 in Q4 2025, $383000.0 in Q3 2025, and $35000.0 in Q2 2025.